Skip to main content

Table 3 Estimated annual GP, specialist and liver ultrasound appointments required in year 4 of the program and sensitivity analysis of incremental service utilisation, compared to baseline (no program)

From: Using a population-based approach to prevent hepatocellular cancer in New South Wales, Australia: effects on health services utilisation

Treatment group Number of people* Annual appointments related to CHB surveillance and/or treatment
   GP appointments
(averaged per GP)
Specialist
(averaged per specialist)
Ultrasound
Routine Surveillance (GP-led) 745 1,303   
Enhanced Surveillance (GP-led) 263 460   263
Interferon (Specialist-led) 8   44 7
Entecavir (Specialist-led) 201   781 195
Other** 236   18 8
Total cohort 1,452 1,763 843 473
Baseline (no program) 1,452 28 84 54
Incremental service utilisation (over no program)
   At 25% program uptake 0 1,734
(5.0)
759
(25.3)
419
   At 10% program uptake 0 694
(2.0)
304
(10.1)
167
   At 65% program uptake 2 4,509
(12.9)
1,974
(65.8)
1,089
With viral load cut-off of 2000 IU/ml at all ages in program 0 1,648
(4.7)
961
(32.0)
557
If ALT cut-off varies, so 20% have high ALT 0 1,908
(5.5)
274
(9.1)
380
If ALT cut-off varies, so 90% have high ALT 0 1,475
(4.2)
1,370
(45.7)
427
If age at enrolment is ≥ 40 years (instead of 35) 0 1,327
(3.8)
616
(20.5)
344
  1. *Estimated at Year 4, after recruitment has been completed
  2. ** other = HCC diagnoses (n = 2); HbeAG seroconversions (n = 47); program dropouts (n = 187)
\